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A B S T R A C T
Purpose
Patients with advanced papillary renal cell carcinoma (PRCC) have limited therapeutic options. PRCC
may involve activation of the MET pathway, for example, through gene ampliﬁcation or mutations.
Savolitinib (AZD6094, HMPL-504, volitinib) is a highly selective MET tyrosine kinase inhibitor. We
report results of a single-arm, multicenter, phase II study evaluating the safety and efﬁcacy of
savolitinib in patients with PRCC according to MET status.
Patients and Methods
Patients with histologically conﬁrmed locally advanced or metastatic PRCC were enrolled and
received savolitinib 600 mg orally once daily. MET-driven PRCCwas deﬁned as any of the following:
chromosome 7 copy gain, focal MET or HGF gene ampliﬁcation, or MET kinase domain mutations.
Efﬁcacy was assessed according to MET status. Safety, toxicity, and patient-reported health-related
quality-of-life outcomes were assessed in all patients.
Results
Of 109 patients treated, PRCCwasMET driven in 44 (40%) andMET independent in 46 (42%); MET
status was unknown in 19 (17%). MET-driven PRCC was strongly associated with response; there
were eight conﬁrmed partial responders with MET-driven disease (18%), but none with MET-
independent disease (P = .002). Median progression-free survival for patients with MET-driven and
MET-independent PRCC was 6.2 months (95% CI, 4.1 to 7.0 months) and 1.4 months (95% CI, 1.4
to 2.7 months), respectively (hazard ratio, 0.33; 95% CI, 0.20 to 0.52; log-rank P , .001). The most
frequent adverse events associated with savolitinib were nausea, fatigue, vomiting, and peripheral
edema.
Conclusion
These data show activity and tolerability of savolitinib in the subgroup of patients with MET-driven
PRCC. Furthermore, molecular characterization of MET status was more predictive of response to
savolitinib than a classiﬁcation based on pathology. These ﬁndings justify investigating savolitinib in
MET-driven PRCC.
J Clin Oncol 35. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Renal cell carcinoma (RCC) is a heterogeneous
disease comprising several histologic subtypes
with different genetic and biochemical charac-
teristics; clear cell RCC is the most frequent,
accounting for 75% to 90% of renal malignan-
cies.1 Of the non–clear cell renal carcinomas,
papillary RCC (PRCC) is the most common, with
a recent study of patients with metastatic non–
clear cell RCC reporting 40% as papillary by
histology, followed by chromophobe RCC (# 5%)
and other less common subtypes.1-3 In 2017, it is
estimated 64,000 new cases of RCC will be di-
agnosed in the United States, equating to up to
6,400 cases of PRCC.4
Somatic PRCC is conventionally classiﬁed
into two histologic subtypes (type 1 and type 2),
with a worse prognosis reported for type 2.5-9
Molecular proﬁling of PRCC corroborates disease
linkage demonstrated by studying rare hereditary
syndromes that lead to RCC. METmutations are
associated with hereditary papillary renal carci-
noma and phenocopy PRCC type 1 histologies,
whereas fumarate hydratase mutations in he-
reditary leiomyomatosis RCC are associated
with a subset of papillary type 2 histologies.10
Author afﬁliations and support information
(if applicable) appear at the end of this
article.
Published at jco.org on June 23, 2017.
Processed as a Rapid Communication
manuscript.
Clinical trial information: NCT02127710.
Corresponding author: Toni K. Choueiri,
MD, Lank Center for Genitourinary
Oncology, Department of Medical
Oncology, Dana-Farber Cancer Institute,
450 Brookline Ave, Dana 1230, Boston,
MA 02215; e-mail: toni_choueiri@dfci.
harvard.edu.
© 2017 by American Society of Clinical
Oncology
0732-183X/17/3599-1/$20.00
ASSOCIATED CONTENT
Appendix
DOI: https://doi.org/10.1200/JCO.
2017.72.2967
DOI: https://doi.org/10.1200/JCO.2017.
72.2967
© 2017 by American Society of Clinical Oncology 1
Downloaded from ascopubs.org by ASTRAZENECA on June 25, 2017 from 212.209.042.182
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Molecular classiﬁcation based on MET or hepatocyte growth
factor (HGF) aberrations may provide more clinically relevant
and reproducible indicators of tumor behavior than histologic
subtype. Two recent cohorts of molecular analyses of PRCC have
conﬁrmed the utility of molecular features to reclassify this
disease.11,12
Activation of the HGF/MET axis triggers tumor growth,
promotes angiogenesis, and induces metastasis.13 METactivation is
also associated with treatment resistance14-16 and correlates with
poor prognosis in many tumor types, including clear cell RCC.17-21
Germline mutations in the MET gene, found on chromosome
7q31, were ﬁrst described in patients with hereditary PRCC. In
addition to MET mutations,22-24 copy number gain of chromo-
some 7 (containing loci of both the MET receptor gene, MET, and
its ligand, HGF) is common, occurring in 45% to 75% of sporadic
PRCC cases, and copy number alterations ofMEToccur in 81% of
type 1 and 46% of type 2 PRCCs.11,12
Currently, prognosis for patients with advanced PRCC is poor,
because of the limited efﬁcacy of currently available therapies,
which were mainly developed for clear cell RCC. In studies of
patients with PRCC, a majority of whom were previously un-
treated, treatment with the multireceptor tyrosine kinase inhibitor
sunitinib typically showed an objective response rate (ORR) of less
than 10% and a median progression-free survival (PFS) of
approximately # 6 months.25-29 These data compare unfavorably
with an ORR of 25% to 30% and a median PFS of 9.5 to 11 months
for patients with treatment-naive clear cell RCC receiving suni-
tinib.30-33 The activity of foretinib, a multikinase inhibitor tar-
geting MET, vascular endothelial growth factor, RON, AXL, and
TIE-2 receptors, against PRCC was assessed in a phase II study.34
Tumor responses were reported in ﬁve of 10 patients with germline
METmutations, compared with ﬁve of 57 patients without such
a mutation, suggesting potential beneﬁt for patients with MET-
driven PRCC.
Savolitinib (AZD6094, HMPL-504, volitinib) is a potent,
selective MET inhibitor being investigated as a targeted therapy for
patients with non–small-cell lung cancer in combination with
osimertinib,35 as well as for patients with advanced or metastatic
PRCC. On the basis of preclinical data and a phase I study showing
partial responses in three of six patients with PRCC,36,37 a single-
arm, multicenter, phase II study was conducted to evaluate the
safety and efﬁcacy of savolitinib in patients with PRCC and to
correlate savolitinib activity with MET pathway alterations.
PATIENTS AND METHODS
Patients
Eligible patients had histologically conﬁrmed locally advanced or
metastatic PRCC, with central and/or local laboratory–conﬁrmed pa-
thology on pretreatment archival tumor tissue. Papillary histology was
independently reviewed by two pathologists; if a consensus was not
reached, a third review was performed by a pathologist at an independent
institute. Other inclusion criteria included: Eastern Cooperative Oncology
Group performance status of 0 or 1, life expectancy $ 12 weeks, age $ 18
years, and adequate hematologic, hepatic, and renal function. Exclusion
criteria included prior or current MET inhibitor treatment, at the dis-
cretion of the study monitor. One patient who had received foretinib 3.5
years earlier was included. The ﬁrst patient was dosed on May 21, 2014.
All patients provided written informed consent. The study was
performed in accordance with ethical principles originating in the Dec-
laration of Helsinki and was consistent with International Conference on
Harmonisation/Good Clinical Practice guidelines, applicable regulatory
requirements, and the AstraZeneca policy on bioethics and human biologic
samples.
Study Design and Objectives
This single-arm, multicenter, global, phase II study evaluated the
safety and efﬁcacy of savolitinib in patients with PRCC irrespective of prior
treatment. The primary objective was to assess savolitinib antitumor ac-
tivity in patients with PRCC and by MET status, as measured by in-
vestigator assessment of ORR according to Response Evaluation Criteria in
Solid Tumors (RECIST; version 1.1).38 Secondary objectives included
change in target lesion tumor size from baseline and PFS (time from ﬁrst
dosing until objective disease progression or death resulting from any
cause) in all patients and byMETstatus according to RECIST (version 1.1).
Study Drug Administration
Patients received savolitinib 600 mg orally once daily, until RECIST
(version 1.1) –deﬁned progression or treatment discontinuation criteria
were met. A treatment cycle was deﬁned as 21 days.
Study Assessments
Screening and baseline assessments were obtained # 28 days before
the ﬁrst savolitinib dose. After baseline evaluation, objective tumor as-
sessments were performed every 6 weeks (6 7 days) for the ﬁrst 12 months
and every 12 weeks thereafter until disease progression. Response to
treatment was assessed by ORR, stable disease, and PFS. Blood samples for
pharmacokinetic, pharmocodynamic, germline DNA, and pharmacoge-
netic analyses were collected.
Patient-reported health-related quality-of-life outcomes and disease-
related symptoms were collected at the start of the ﬁrst three treatment
cycles and then every 6 weeks, up to and including at discontinuation. The
Functional Assessment of Cancer Therapy (FACT) –General, FACT Kidney
Symptom Index-19 (FKSI-19), and European Quality of Life 5-Dimensions
5-Levels (EQ-5D-5L) were used.
The safety and tolerability of savolitinib were assessed according to
Common Terminology Criteria for Adverse Events (version 4.03). Adverse
events (AEs) and medical/surgical history were classiﬁed according to the
Medical Dictionary for Regulatory Activities (version 18.1) and recorded
from on or after the ﬁrst dose until 30 days after the last dose of savolitinib.
End of study for ORR was January 29, 2016; data cutoff for PFS was June
27, 2016.
Assessment of MET Pathway Status
Next-generation sequencing of archival tumor tissue was analyzed
using a targeted 400-gene panel (version T7; Foundation Medicine,
Cambridge, MA) as previously described.39 PRCC was conﬁrmed as MET
driven by identiﬁcation of MET copy number gain (either chromosome 7
gain or a focalMETampliﬁcation of$ six copies),HGF gene ampliﬁcation
($ six copies), or MET kinase domain mutations (allele frequency. 5%).
The Appendix (online only) provides more information on assessment of
MET status. Focal MET ampliﬁcations were conﬁrmed by ﬂuorescent
in situ hybridization.
Statistical Considerations
The trial size was designed to detect a response rate (ORR) of greater
than 10% in patients with MET-driven disease while accounting for the
estimated prevalence of this target population. A sample size of 50 patients
with MET-driven PRCC allowed this signal detection at a 90% two-sided
conﬁdence level with at least 80% power assuming the true response rate
was 25% or better. Analyses of outcome measures were descriptive, and
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tests for signiﬁcant differences were conducted between patients with
MET-driven and MET-independent PRCC.
RESULTS
Patients and Treatment
In total, 111 patients were enrolled, and 109 received at least
one dose of savolitinib (treatment population). Baseline de-
mographic and clinical characteristics are listed in Table 1. Patient
demographics were as expected for a population with advanced
PRCC.Most patients (n = 107; 98%) hadmetastatic disease, and 49
(45%), 80 (73%), and 22 (20%) had previously undergone systemic
therapy, nephrectomy, or radiotherapy, respectively. Overall, 28
(26%) had received sunitinib.
PRCC was MET driven in 44 patients (40%) and MET in-
dependent in 46 (42%). MET status was unknown in 19 patients
(17%). Baseline characteristics of patients with MET-driven and
-independent disease were generally similar (Table 1). In 25 pa-
tients (23%), it was not possible to deﬁne the tumor as type 1 or 2,
partly as a result of limited tissue available for central review,
because typically only a single block from each patient case is
provided. The proportions classiﬁed as type 1 and type 2 PRCC by
central review differed according to MET status; among patients
with MET-driven PRCC, 12 (27%) were classiﬁed as type 1 and 23
(52%) as type 2, whereas among patients with MET-independent
Table 1. Patient Demographic and Baseline Clinical Characteristics
Characteristic
No. (%)
MET Driven
(n = 44)
MET Independent
(n = 46)
MET Unknown
(n = 19)
Total
(N = 109)
Age, years
Median 64 64 58 64
Range 23-87 29-75 37-80 23-87
Sex
Female 12 (27) 11 (24) 8 (42) 31 (28)
Male 32 (73) 35 (76) 11 (58) 78 (72)
Race
White 38 (86) 40 (87) 18 (95) 96 (88)
Black or African American 5 (11) 2 (4) 1 (5) 8 (7)
Asian 0 (0) 1 (2) 0 (0) 1 (1)
Other 1 (2) 3 (7) 0 (0) 4 (4)
ECOG performance status
0 18 (41) 25 (54) 8 (42) 51 (47)
1 26 (59) 21 (46) 11 (58) 58 (53)
PRCC conﬁrmation*
Yes 35 (80) 39 (85) 10 (53) 84 (77)
No 9 (21) 7 (15) 9 (47) 25 (23)
Renal cell classiﬁcation*
Type 1 PRCC 12 (27) 2 (4) 2 (11) 16 (15)
Type 2 PRCC 23 (52) 37 (80) 8 (42) 68 (62)
Subtype unclassiﬁable 9 (21) 7 (15) 9 (47) 25 (23)
Tumor grade*†
Low 0 (0) 4 (9) 1 (5) 5 (5)
Intermediate 8 (18) 11 (24) 5 (26) 24 (22)
High 12 (27) 15 (33) 4 (21) 31 (28)
Missing‡ 24 (55) 16 (35) 9 (47) 49 (45)
MSKCC risk group
Favorable 3 (7) 10 (22) 2 (11) 15 (14)
Intermediate 28 (64) 14 (30) 7 (37) 49 (45)
Poor 2 (5) 4 (9) 4 (21) 10 (9)
Missing 11 (25) 18 (39) 6 (32) 35 (32)
No. of prior systemic therapies
0 26 (59) 23 (50) 11 (58) 60 (55)
1 12 (27) 10 (22) 3 (16) 25 (23)
2 3 (7) 5 (11) 2 (11) 10 (9)
$ 3 3 (7) 8 (17) 3 (16) 14 (13)
Prior immunotherapy 6 (14) 3 (7) 1 (5) 10 (9)
Prior radiotherapy 9 (21) 10 (22) 3 (16) 22 (20)
Prior surgery
Nephrectomy 32 (73) 35 (76) 13 (68) 80 (73)
Lymphadenectomy 8 (18) 9 (20) 1 (5) 18 (17)
Adrenalectomy 4 (9) 4 (9) 2 (11) 10 (9)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; MSKCC, Memorial Sloan Kettering Cancer Center; PRCC, papillary renal cell carcinoma.
*On the basis of central laboratory data; in 25 patients, conﬁrmation was not possible partly because of limited tissue available for central review (typically only a single
block from each patient case is provided) or the subtype of PRCC was not considered classiﬁable.
†Modiﬁed Fuhrman nuclear grade: low, grade 1 or 2; intermediate, grade 3; and high, grade 4.
‡Mainly because of missing baseline lactate dehydrogenase values. Percentages may not total 100% because of rounding.
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PRCC, the proportions were two (4%) and 37 patients (80%),
respectively (Table 1).
Objective Disease Response
In the overall treatment population, the ORR was 7%.
However, when assessed by MET status, the ORR was signiﬁcantly
higher in patients with MET-driven PRCC (eight partial responses
[18%; PRs] among 44 patients) than with MET-independent
PRCC (zero [0%] PRs among 46 patients; P = .002; Table 2).
Categorization of MET-driven PRCC by histologic subtype showed
two (17%) of 12 patients with type 1 and one (4%) of 23 patients
with type 2 PRCC exhibited a PR. Five patients with a PR were not
classiﬁed as having either type 1 or 2 disease by central review.
Stable disease was achieved in 22 patients (50%) with MET-
driven PRCC and 11 (24%) with MET-independent disease
(Table 2). Waterfall plots for maximal tumor response by MET
status are shown in Figure 1. Of 44 patients with MET-driven
PRCC, 27 (61%) experienced some tumor shrinkage (range,20.7%
to 266% shrinkage), whereas nine (20%) of 46 patients with
MET-independent PRCC had any tumor shrinkage (range, 20.5%
to 220% shrinkage).
PFS and Duration of Response
In the treatment population, 82 patients (75%) experienced
progression, died, or discontinued therapy, and 27 (25%) con-
tinued to receive study drug or remained in follow-up at end of
study. As of the June 27, 2016, data cutoff, 41 patients had died and
19 were still receiving savolitinib. Disease progression occurred in
33 (75%), 44 (96%), and 14 patients (74%) with MET-driven,
MET-independent, and MET-unknown PRCC, respectively. Pa-
tients with MET-driven PRCC had a signiﬁcantly longer median
PFS than those with MET-independent disease (6.2 months; 95%
CI, 4.1 to 7.0 months v 1.4 months; 95% CI, 1.4 to 2.7 months,
respectively). The PFS hazard ratio (HR) for patients with MET-
driven PRCC was 0.33 (95% CI, 0.20 to 0.52) compared with MET-
independent PRCC (log-rank P, .001; Fig 2). After discontinuation
of savolitinib, 10 (23%) and 14 patients (30%) with MET-driven
and MET-independent disease, respectively, received additional
lines of therapy for PRCC. Of the eight patients exhibiting a PR,
six were still responding to treatment at data cutoff, with a duration
of response of 2.4 to 16.4 months. Two patients who achieved
a PR subsequently experienced progressive disease after 1.8 and
2.8 months.
Activity by Lines of Prior Therapy
Of the patients achieving a PR, three had received no prior
therapy and ﬁve had received one or more previous lines of
treatment. For the 38 patients (35%) with a best response of stable
disease, 24 had received no previous therapy and 14 had received
one or more prior lines of treatment. Among patients with pro-
gressive disease, 26 had received no prior therapy and 22 had
received one or more lines of treatment. Prior cancer therapies are
listed in Appendix Table A1 (online only).
Patient-Reported Outcomes: Quality of Life
Quality-of-life data were collected via the FACT-G, FKSI-19,
and EQ-5D-5L questionnaires. Overall, during savolitinib treat-
ment, scores for symptoms and quality of life were maintained at
similar values to those reported at baseline, irrespective of the
questionnaire used (Appendix Table A2, online only). This suggests
that, among patients completing the questionnaires, there was little
change in these outcomes during the study.
Safety and Tolerability
The overall incidence of AEs and those considered treatment
related occurring in $ 3% of patients who received at least one
dose of savolitinib are listed in Table 3. Most patients (88%) ex-
perienced at least one AE considered by the investigator to be
related to study drug. Abnormal liver function tests were reported
in 20% of patients, irrespective of METstatus. The most frequently
observed hepatic AEs were increased blood AST in 12 patients
(11%) and ALT in 11 patients (10%), which were grade 3 or higher
in four (4%) and ﬁve patients (5%), respectively. Three patients
reported serious AEs considered at least related to treatment; these
were: grade 3 pneumonitis, grade 4 elevated transaminases, and
grade 4 drug-induced liver injury, which led to death resulting
from hepatic encephalopathy.
A total of 13 AEs in nine patients (6%) led to drug discon-
tinuation. These AEs included increased ALTand peripheral edema
(both in two patients) and individual events of increased AST,
proteinuria, pain, nausea, vomiting, fatigue, and embolism. Dosing
was delayed for 47 patients (43%); in 38 (35%) of these patients,
the delay was because of an AE. Fourteen patients (13%) had dose
reductions as a result of an AE at some time during the study.
DISCUSSION
To our knowledge, this is the largest study of patients with ad-
vanced or metastatic PRCC with central pathology review and
biomarker analysis used to deﬁne MET-driven and MET-
independent PRCC. Patients experiencing responses in this
study were found only in the group with MET-driven disease,
indicating that savolitinib may suppress MET-driven tumor
growth. Furthermore, PFS for those with MET-driven tumors was
signiﬁcantly longer (6.2 months) compared with those with MET-
independent disease (1.4 months). Continued long-term follow-up
Table 2. Tumor Responses in Overall Treatment Population and byMET Status
RECIST
Response
No. (%)
MET
Driven
(n = 44)
MET
Independent
(n = 46)
MET
Unknown
(n = 19)
Total
(N = 109)
PR* 8 (18)† 0 (0) 0 (0) 8 (7)
SD 22 (50) 11 (24) 5 (26) 38 (35)
PD 11 (25) 28 (61) 9 (47) 48 (44)
NE 3 (7) 7 (15) 5 (26) 15 (14)
Abbreviations: PR, partial response; SD, stable disease; PD, progressive dis-
ease; NE, not evaluable.
*Unconﬁrmed responses excluded.
†P = .002 versus MET-independent subgroup (Fisher’s exact test). Responses
assessed according to RECIST (version 1.1).
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will allow further assessment of the difference in PFS and provide
data on overall survival.
The analysis ofMETmutations, copy number gain, or gain of
chromosome 7 in patients deﬁned as having type 1 or type 2 PRCC
on the basis of pathology challenges the view that aberrations in
MET are mainly associated with type 1 PRCC. Our study found
MET copy number gain (either chromosomal or focal) in 72% of
type 1 PRCCs and 46% of type 2 PRCCs, which is comparable to
previous reports of MET copy number gain in 81% and 46% of
type 1 and type 2 PRCCs, respectively.11 The frequency of MET
kinase domain mutations identiﬁed here is also similar to data
from The Cancer Genome Atlas Research Network of 15%, 2%,
and 12% in type 1, type 2, and unclassiﬁed PRCCs, respectively.12
Of note, the The Cancer Genome Atlas publication reported any
MET gene mutation, whereas our study considered only kinase
domain mutations. This may explain the slightly reduced fre-
quency ofMETmutations in our study and suggests the molecular
features of PRCC reported here are comparable to those of pre-
viously published cohorts. Overall, METstatus was more predictive
of response to savolitinib in our study than a classiﬁcation based on
pathology; all partial responders had archival tumor samples that
harbored a copy number gain in the MET pathway (HGF,MET, or
chromosome 7), some in combination with a MET kinase domain
mutation. This suggests that genomic proﬁling can better identify
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Fig 1. Best percentage change in tumor size
from baseline according to MET status. Investigator-
assessed measurements of target lesion size using
RECIST (version 1.0) in patients with papillary renal
cell carcinoma (PRCC) and MET status assessment
with measurable disease at baseline and at least one
postbaseline measurement. (A) MET-driven PRCC
(n = 40); (B) MET-independent PRCC (n = 41); and (C)
MET status unknown (n = 16).
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patients whomay respond to savolitinib than can the type 1 or type
2 histologic subtype, adding relevance to the use of genomic
proﬁling in such studies. MET pathway PRCC tumors have also
been identiﬁed by others to not only be associated with type 1
histology.12
Overall, savolitinib was generally well tolerated, with the
three most common AEs (nausea, fatigue, and vomiting) also
commonly reported previously by patients with PRCC receiving
foretinib.34 Other AEs occurring in $ 10% of patients in our
study were peripheral edema, ALT and AST increases, serum
creatinine increase, and decreased appetite. Increased ALT and
AST have been reported in patients with PRCC treated with
foretinib (in 22% and 24% of patients, respectively) and sunitinib
(up to 74% of patients).26,27,34 A majority of these events, as in
our study, were grade 1 or 2. Dosing of savolitinib was only
reduced in four patients because of abnormal liver function, and
two patients discontinued treatment because of abnormal ASTor
ALT levels.
Following the history of evaluating MET inhibitors for the
treatment of RCC, these results with savolitinib are encouraging.
There have been numerous reasons why earlier MET inhibitors
have failed during drug development. For example, tivantinib was
reported to be a selective MET inhibitor, but a subsequent study
reported similar suppression of both MET-dependent and MET-
independent tumor cell lines, via inhibition of microtubule
polymerization.40 Less selective multikinase inhibitors may not
achieve the extent or duration of MET pathway attenuation
necessary for suppression of MET-mediated migration and in-
vasion at tolerated doses. Most importantly, patients have not been
appropriately selected in the past; it is now increasingly recognized
that high MET protein levels (usually detected by immunohisto-
chemistry) do not always correlate with response or survival out-
comes.41 In a phase II study of foretinib, tumor responses were
reported in ﬁve of 10 patients with germline METmutations com-
pared with 9% of patients without MET mutations.34 Recently, in
a small study of type 1 PRCC, patients with MET-driven disease
(METmutation positive [n = 4] and MET ampliﬁcation [n = 2])
responded to treatment with crizotinib, an inhibitor of MET,
ALK, and ROS1.42 The current interest in MET inhibitors for the
treatment of PRCC is demonstrated by the initiation of a ran-
domized phase II trial comparing the efﬁcacy of several MET
kinase inhibitors, including savolitinib (ClinicalTrials.gov iden-
tiﬁer: NCT02761057). In that cooperative group study, patients
are not being selected based on METmutation status, although
tumor response by MET mutation and expression level is an
additional outcome.
Limitations of our study include the single-arm design, and
therefore the inherent lack of a comparator group, and the
relatively small number of patients with MET-driven disease.
Prognostic information for MET in PRCC is also lacking because
of the single-arm design.
In summary, these results conﬁrm that savolitinib, a potent
and selective small-molecule MET kinase inhibitor, holds
promise as a personalized treatment for patients with metastatic
MET-driven PRCC. Our study identiﬁed a deﬁned molecular
group and highlights the prevalence of MET-driven disease,
including patients with ligand-dependent (ie,HGF ampliﬁcation)
and -independent PRCC who responded to treatment. These data
support the hypothesis that savolitinib has antitumor activity in
patients with MET-driven PRCC and justiﬁes the recently
launched phase III trial comparing savolitinib with sunitinib in
a population of patients with MET-driven PRCC (ClinicalTrials.
gov identiﬁer: NCT03091192)
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free survival (PFS), deﬁned as time from the
date of ﬁrst dosing until the date of objective
disease progression or death resulting from any
cause, in patients with papillary renal cell car-
cinoma by MET status (treatment population).
(+) indicates censored event.
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Table 3. Overall Incidence of AEs and Those Considered Related to Savolitinib Treatment Occurring in $ 3% of Patients
AE*
No. (%)
Treatment Population
(N = 109)
Grade 1-2 Grade $ 3 Total
Any AE 57 (52) 51 (47) 108 (99)
Any treatment-related AE† 75 (69) 21 (19) 96 (88)
Any SAE (including death) 23 (21)
Death
Related to PRCC or disease progression 32 (29)
Considered treatment related 1 (, 1)
Treatment discontinuation
Due to any AE 9 (8)
Due to any SAE 3 (3)
AEs considered treatment-related occurring in $ 3% of
patients†
Nausea 42 (39) 0 (0) 42 (39)
Fatigue 21 (19) 2 (2) 23 (21)
Vomiting 18 (17) 1 (, 1) 19 (17)
Peripheral edema 17 (16) 1 (, 1) 18 (17)
AST increased 9 (8) 3 (3) 12 (11)
Blood creatinine increased 12 (11) 0 (0) 12 (11)
ALT increased 6 (6) 5 (5) 11 (10)
Decreased appetite 10 (9) 1 (, 1) 11 (10)
Diarrhea 9 (8) 0 (0) 9 (8)
Anemia 6 (6) 1 (, 1) 7 (6)
Constipation 7 (6) 0 (0) 7 (6)
Dysgeusia 7 (6) 0 (0) 7 (6)
Mucosal inﬂammation 6 (6) 0 (0) 6 (6)
Proteinuria 5 (5) 1 (, 1) 6 (6)
Stomatitis 5 (5) 0 (0) 5 (5)
Hyponatremia 2 (2) 3 (3) 5 (5)
Pruritus 5 (5) 0 (0) 5 (5)
Edema 4 (4) 0 (0) 4 (4)
Weight decreased 4 (4) 0 (0) 4 (4)
Hyperkalemia 3 (3) 1 (, 1) 4 (4)
Hypokalemia 4 (4) 0 (0) 4 (4)
Back pain 4 (4) 0 (0) 4 (4)
Rash (maculopapular) 3 (3) 1 (, 1) 4 (4)
Peripheral swelling 3 (3) 0 (0) 3 (3)
Fluid retention 3 (3) 0 (0) 3 (3)
Hypoalbuminemia 3 (3) 0 (0) 3 (3)
Hypomagnesaemia 3 (3) 0 (0) 3 (3)
Arthralgia 3 (3) 0 (0) 3 (3)
Joint swelling 3 (3) 0 (0) 3 (3)
Myalgia 3 (3) 0 (0) 3 (3)
Lethargy 3 (3) 0 (0) 3 (3)
Rash 3 (3) 0 (0) 3 (3)
Abbreviations: AE, adverse event; PRCC, papillary renal cell carcinoma; SAE, serious adverse event.
*Patients with multiple events in the same category are counted only once in that category. Patients with events in more than one category are counted once in each of
those categories.
†As assessed by the investigator. Includes AEs with an onset date on or after the date of ﬁrst dose and up to and including 30 days after the date of last dose of
savolitinib. Grade of AEs reported according to Common Terminology Criteria for Adverse Events (version 4.03).
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Appendix
Investigators Enrolling Patients
The following investigators also enrolled patients in this study: Ulka Vasishampayan (Karmanos Cancer Institute, Detroit, MI),
Walter Stadler (University of Chicago, Chicago, IL), Jennifer Knox (Princess Margaret Hospital, Toronto, Ontario, Canada), Balaji
Venugopal (Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom), Pablo Maroto (Hospital de Sant Pau, Barcelona,
Spain), Howard Burris (Sarah Cannon Research Institute [SCRI] –Tennessee Oncology, Nashville, TN), Lowell Hart (SCRI–Florida
Cancer Specialists, West Palm Beach, FL), Kathryn Fife (Addenbrookes and Cambridge University Hospitals, Cambridge, United
Kingdom), Georg Bjarnason (Sunnybrook Research Institute, Toronto, Ontario, Canada), Naveen Basappa (University of Alberta
Cross Cancer Institute, Edmonton, Alberta, Canada), Robert Hawkins (The Christie Clinic, Manchester, United Kingdom),
Sandhya Srinivas (Stanford University, Stanford, CA), Guru Sonpavde (University Alabama at Birmingham, Birmingham, AL),
Daniel Vaena (University of Iowa, Iowa City, IA), Ana Molina (Weill Cornell Medicine, New York, NY), and Thomas Hutson
(Baylor Sammons Cancer Center, Dallas, TX).
Methods
Next-generation sequencing (NGS) of archival tumor tissue was analyzed using a targeted 400-gene panel (version T7;
Foundation Medicine, Cambridge, MA) as previously described.39 Brieﬂy, DNA extraction (a minimum of 50 ng of DNA was
required to pass quality-control criteria) and library construction from 40 microns of formalin-ﬁxed parafﬁn-embedded tumor
tissue was used for hybridization capture with probes for each exon of 400 genes, including 23 genes on chromosome 7 and 4,200
single-nucleotide polymorphisms across the genome for proprietary analytics that determined the purity and ploidy of the sample
genome, chromosome 7 copy number relative to the genome ploidy (where one additional copy including the MET locus was
considered chromosome 7 gain), and MET kinase domain mutations and MET or HGF gene focal ampliﬁcation.
METmutations previously identiﬁed in papillary renal cell carcinoma (PRCC) were also identiﬁed in this trial, and all but one
are found in the kinase domain and include (NM_000245) V1092I, H1094L (n = 2), L1195F (n = 2), M1131T, and M1250T. One
METmutationwas identiﬁed outside the kinase domain, V37A, which has not been previously reported (Durinck S, et al: Nat Genet
47:13-21, 2015)11,12 and was not associated with savolitinib response; therefore, only kinase domain MET mutations were
considered MET driven for this trial. The copy number range for focal MET locus ampliﬁcation (, 20 Mb by targeted NGS)
identiﬁed in this PRCC trial was three, seven (n = 2), eight (n = 2), nine, 10, and 12, where patient samples harboring 6 seven
copies, but not three copies, correlated with savolitinib response. Furthermore, the NGS assay has been analytically validated for six
copies as a cutoff for focal ampliﬁcations.39 Taken together, only focal gains of more than six copies were classiﬁed as MET driven in
this trial. Focal MET ampliﬁcations identiﬁed by targeted NGS were conﬁrmed by ﬂuorescent in situ hybridization (FISH). MET
FISH has been used as a method for patient selection to identifyMET-ampliﬁed tumors in other indications, such as non–small-cell
lung cancer, gastric cancer, and colorectal cancer (Cappuzzo F, et al: J Clin Oncol 27:1667-1674, 2009; Kawakami H, et al:
Oncotarget 4:9-17, 2013),15 and has been clinically validated as a tool for other receptor tyrosine kinase–driven diseases, such as
human epidermal growth factor receptor 2 in breast cancer (Slamon D, et al: N Engl J Med 365:1273-1283, 2011), and therefore
served as a robust orthogonal method to conﬁrm the MET ampliﬁcation ﬁndings in the NGS proﬁling or PRCC tumor samples
from this trial.
jco.org © 2017 by American Society of Clinical Oncology
Savolitinib Safety and Efﬁcacy in Papillary Renal Cell Carcinoma
Downloaded from ascopubs.org by ASTRAZENECA on June 25, 2017 from 212.209.042.182
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Table A2. Change From Baseline of Overall FACT-G, FKSI-19, and EQ-5D-5L Scores by MET Status at Selected Time Points
Cycle
MET Driven MET Independent MET Unknown Total
No. Mean (SD) No. Mean (SD) No. Mean (SD) No. Mean (SD)
FACT-G
2 19 5.1 (9.8) 18 24.6 (8.6) 10 22.7 (10.4) 47 20.3 (10.3)
7 6 8.7 (13.2) 2 26.0 (2.8) 1 1.0 9 4.6 (12.4)
13 1 21.8 1 21.0 0 0 2 10.4 (16.1)
FKSI-19
2 34 2.3 (8.8) 34 23.1 (8.5) 16 23.1 (6.8) 84 20.9 (8.7)
7 15 3.9 (9.0) 4 26.6 (6.0) 2 1.5 (6.4) 21 1.7 (9.1)
13 5 9.1 (7.5) 2 26.0 (5.7) 0 0 7 4.8 (9.8)
EQ-5D-5L
2 15 26.3 (12.2) 17 1.0 (20.6) 9 1.0 (5.3) 41 21.7 (15.5)
7 5 29.8 (11.8) 2 25.5 (0.7) 1 25.0 8 28.1 (9.3)
13 0 0 1 , 1 0 0 1 , 1
Abbreviations: EQ-5D-5L, European Quality of Life 5-Dimensions 5-Levels; FACT-G, Functional Assessment of Cancer Therapy–General; FKSI, FACT Kidney Cancer
Symptom Index; SD, standard deviation.
Table A1. Prior Cancer Therapy
Prior Treatment
No. (%)
MET Driven
(n = 44)
MET Independent
(n = 46)
MET Unknown
(n = 19)
Total
(N = 109)
Fluorouracil 0 (0) 1 (2) 0 (0) 1 (1)
Axitinib 1 (2) 5 (11) 2 (11) 8 (7)
Bevacizumab 2 (5) 1 (2) 1 (5) 4 (4)
Buparlisib 0 (0) 1 (2) 0 (0) 1 (1)
Carboplatin 0 (0) 0 (0) 1 (5) 1 (1)
Cisplatin 0 (0) 0 (0) 1 (5) 1 (1)
Denosumab 0 (0) 1 (2) 0 (0) 1 (1)
Erlotinib 1 (2) 0 (0) 0 (0) 1 (1)
Everolimus 4 (9) 6 (13) 2 (11) 12 (11)
Foretinib 0 (0) 1 (2) 0 (0) 1 (1)
Gemcitabine 0 (0) 1 (2) 1 (5) 2 (2)
Interferon/interleukin 0 (0) 1 (2) 1 (5) 2 (2)
Ipilimumab/nivolumab 1 (2) 0 (0) 0 (0) 1 (1)
Paclitaxel 0 (0) 0 (0) 1 (5) 1 (1)
Pazopanib 4 (9) 11 (24) 1 (5) 16 (15)
Radium-223 0 (0) 0 (0) 1 (5) 1 (1)
Sapanisertib 0 (0) 1 (2) 0 (0) 1 (1)
Sorafenib 0 (0) 2 (4) 1 (5) 2 (2)
Sunitinib 10 (23) 14 (30) 4 (21) 28 (26)
Temsirolimus 3 (7) 4 (9) 1 (5) 8 (7)
Tivantinib/erlotinib 0 (0) 0 (0) 1 (5) 1 (1)
Vorinostat/ridaforolimus 0 (0) 0 (0) 1 (5) 1 (1)
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